Innate Pharma Balance Sheet Health
Financial Health criteria checks 4/6
Innate Pharma has a total shareholder equity of €28.8M and total debt of €34.9M, which brings its debt-to-equity ratio to 121.3%. Its total assets and total liabilities are €151.5M and €122.7M respectively.
Key information
121.3%
Debt to equity ratio
€34.92m
Debt
| Interest coverage ratio | n/a |
| Cash | €91.80m |
| Equity | €28.80m |
| Total liabilities | €122.70m |
| Total assets | €151.50m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: IDDA's short term assets (€111.6M) exceed its short term liabilities (€38.2M).
Long Term Liabilities: IDDA's short term assets (€111.6M) exceed its long term liabilities (€84.5M).
Debt to Equity History and Analysis
Debt Level: IDDA has more cash than its total debt.
Reducing Debt: IDDA's debt to equity ratio has increased from 1.3% to 121.3% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IDDA has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if IDDA has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.